[Are gestagens suitable for lowering the membrane potential of the uterine muscle and eliminating the need for beta-mimetics?].
L
L
Spätling
D000077713:17 alpha-Hydroxyprogesterone Caproate; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000627:therapeutic use*; D007231:Infant, Newborn; D008564:Membrane Potentials / Q000187:drug effects; D009215:Myometrium / Q000187:drug effects*; D011247:Pregnancy; D045167:Progesterone Congeners / Q000627:therapeutic use*; D015145:Tocolysis / Q000379:methods*; D014590:Uterine Contraction / Q000187:drug effects
D000318:Adrenergic beta-Agonists; D006908:Hydroxyprogesterones; D045167:Progesterone Congeners; D000077713:17 alpha-Hydroxyprogesterone Caproate
Sind Gestagene zur Senkung des Membranpotentials der Uterusmuskelzelle und damit zur Einsparung von Betamimetika geeignet?